Pharmaceutical supply chains are global, high-value, and now high-tariff. Companies importing active ingredients and finished products, then exporting to other markets, are sitting on some of the largest recoverable duty pools in the industry, and a Section 232 action just opened a new one.
Pharmaceutical importers with an export footprint frequently qualify on more than one front at once.
The April 2, 2026 proclamation adjusting imports of pharmaceuticals and pharmaceutical ingredients expressly provides for duty drawback, an exception among Section 232 actions, most of which do not. Duties paid on covered products that are later exported are recoverable at 99%.
Many active pharmaceutical ingredients and intermediates sourced from China carry Section 301 duties. Those additional duties are drawback-eligible when the resulting product is exported.
Standard customs duties plus the merchandise processing and harbor maintenance fees are fully recoverable under 19 U.S.C. 1313, on both re-exported ingredients and finished dosage forms shipped abroad.
Two recovery patterns dominate pharmaceutical drawback, and most manufacturers use both.
Import active ingredients and excipients, manufacture finished pharmaceuticals in the U.S., and export them. The duties paid on the imported inputs are recovered when the finished product ships abroad, matched by direct identification or substitution of the same 8-digit HTS.
Import finished pharmaceuticals or ingredients and re-export them in essentially the same condition, a common pattern in distribution and clinical supply, and recover the duties under unused merchandise drawback.
Yes. The April 2, 2026 Section 232 pharmaceutical proclamation provides for duty drawback, unlike most Section 232 actions. See our tariff refunds guide for the full proclamation-by-proclamation picture.
Active ingredients, excipients, and finished dosage forms on which duties, Section 301 tariffs, or the eligible Section 232 pharma tariff were paid, where the goods or a qualifying substitute are later exported or destroyed within five years.
Often yes, re-exporting imported product in essentially the same condition is classic unused merchandise drawback. The key is documentation linking the import to the export.
A licensed U.S. Customs broker with pharmaceutical drawback experience will review your entries, confirm eligibility across all three duty pools, and file end to end.